Latest advances on interventions that may prevent, delay or ameliorate dementia

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 3, 2011, Pages 161-173

  Wilson, Danielle ^a   Ritchie, Craig W ^a   Peters, Ruth ^b   Ritchie, Karen ^c  

^a WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

ageing; Alzheimer's disease; cognitive decline; delay; dementia; prevent; risk factors

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NOOTROPIC AGENT; PLACEBO; TAU PROTEIN; VITAMIN B GROUP;

AGE; ALZHEIMER DISEASE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COGNITION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG SAFETY; ENVIRONMENTAL FACTOR; ENZYME REGULATION; GINSENG; HEART PROTECTION; HEREDITY; HUMAN; HYPERTENSION; LIFESTYLE; MENTAL FUNCTION; MILD COGNITIVE IMPAIRMENT; MITOCHONDRION; MOLECULAR STABILITY; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRAINING;

EID: 79960072862     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622310397636     Document Type: Review

References (98)

1. Aisen P. Scheider L. Sano M. Diaz-Arrastia R. Dyck C. Weiner M. et al. for the Alzheimer Disease Cooperative Study Group. (2008) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease. JAMA 300: 1774–1783.
2. Akhondzadeh S. Sabet M. Harirchian M. Togha M. Cheraghmakini H. Razeghi S. et al. (2010) A 22-week, multicenter, randomised, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology 207: 637–643.
3. Alexopoulos G. Meyers B. Young R. Mattis S. Kakuma T. (1993) The course of geriatric depression with ‘reversible dementia’: a controlled study. Am J Psychiatry 150: 1693–1699.
4. Allen K.V. Frier B.M. Strachan M.W.J. (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490: 169–175.
5. Andel R. Crowe M. Pedersen N.L. Fratiglioni L. Johansson B. Gatz M. (2008) Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins. J Gerontol A Biol Sci Med Sci 63: 62–66.
6. Anstey K.J. Mack H.A. Cherbuin N. (2009) Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psychiatry 17: 542–555.
7. Barberger-Gateau P. Letenneur L. Deschamps V. Peres K. Dartigues J. Rnaud S. (2002) Fish, meat and risk of dementia: cohort study. BMJ 325: 932–933.
8. Barker W. Luis C. Kashuba A. Luis M. Harwood D. Loewenstein D. et al. (2002) Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 16: 203–212.
9. Bellow K. Pigeon J. Stang P. Fleishman W. Gardner R. Baker W. (2004) Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 18: 208–213.
10. Bendlin B.B. Carlsson C.M. Gleason C.E. Johnson S.C. Sodhi A. Gallagher C.L. et al. (2010) Midlife predictors of Alzheimer's disease. Maturitas 65: 131–137.
11. Brookmeyer R. Gray S. Kawas C. (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88: 1337–1342.
12. Biessels G.J. Staekenborg S. Brunner E. Brayne C. Scheltens P. (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet 5: 64–74.
13. Bulic B. Pickhardt M. Mandelkow E.M. Mandelkow E. (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology [ePub ahead of print].
14. Collins R. Peto R. Armitage J. (2002) The MRC / BHF Heart Protection Study: preliminary results. Int J Clin Practice 56: 53–56.
15. Comas-Herrera A. Wittenberg R. Pickard L. Knapp M. (2007) Cognitive impairment in older people: future demand for long-term care services and the associated costs. Int J Ger Psych 22: 1037–1045.
16. Cramer C. Haan M.N. Galea S. Langa K.M. Kalbfleisch J.D. (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71: 344–350.
17. Dai Q. Borenstein A. Wu Y. Jackson J. Larson E. (2006) Fruit and vegetable juices and Alzheimer's disease: the Kame project. Am J Med 119: 751–759.
18. Devore E. Grodstein F. Rooij F. Hofman A. Stampfer M. Witteman J. et al. (2010) Dietary antioxidants and long-term risk of dementia. Arch Neurol 67: 819–825.
19. Doody R.S. Gavrilova S.I. Sano M. Thomas R.G. (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372: 207–215.
20. Dotson V.M. Beydoun M.A. Zonderman A.B. (2010) Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 75: 27–34.
21. Duron E. Rigaud A. Dubail D. Mehrabian S. La tour F. Seux M. et al. (2009) Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. Am J Hypertension 22: 1020–1024.
22. Feigen V. Ratnasabapathy Y. Anderson C. (2005) Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 229-230: 151–155.
23. Feldman H. Doody R. Kivipelto M. Sparks D. Waters D. Jones R. et al. (2010) Randomised controlled trial of atorvastatin in mild to moderate Alzheimer disease. Neurology 74: 956–964.
24. Ferri C.P. Prince M. Brayne C. Brodaty H. Fratiglioni L. Ganguli M. et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112–2117.
25. Fratiglioni L. Launer L. Anderson K. Breteler M. Copeland J. Dartigues Lobo A. et al. for the Neurologic Diseases in the Elderly Research Group. (2000 a) Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology 54 (11): S10–S15.
26. Fratiglioni L. Paillard-Borg S. Winblad B. (2004) An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 3: 343–353.
27. Fratiglioni L. Wang H.X. Kjerstin Ericsson B.A. Maytan M. Winblad B. (2000 b) Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet 355: 1315–1319.
28. Gold G. (1998) Reevaluating the role of vascular changes in the differential diagnosis of Alzheimer's disease and vascular dementia. Eur Neurol 40: 121–129.
29. Golomb B.A. Criqui M.H. White H.L. Dimsdale J.F. (2004) The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 25: 178–202.
30. Green R.C. Schneider L.S. Amato D.A. Beelen A.P. et al. (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. AMA 302: 2557–2564.
31. Grimley Evans J. Areosa Sastre A. (2009) Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 1: CD003804–CD003804. DOI: 10.1002/14651858.CD003804.
32. Haag M.D.M. Hofman A. Koudstaal P.J. Stricker B.H.C. Breteler M.M.B. (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80: 13–17. DOI: 10.1136/jnnp.2008.150433.
33. Hakansson K. Rovio S. Helkala E.L. Vilska A.R. Winblad B. Soininen H. et al. (2009) Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ 339: b2462–b2462.
34. Hall C.B. Lipton R.B. Sliwinski R.B. Katz M.J. Derby C.A. Verghese J. et al. (2009) Cognitive activities delay onset of memory decline in persons who develop dementia. Neurology 73: 356–361.
35. Hamer M. Chida Y. (2009) Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 39: 3–11.
36. Hampel H. Ewers M. Bürger K. Annas P. Mörtberg A. Bogstedt A. et al. (2009) Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70: 922–931.
37. Heart Protection Study Collaborative Group. (2002) MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo controlled trial. Lancet 360: 7–22.
38. Helzner E. Luchsinger J. Scarmeas N. Cosentino S. Brickman A. Glymour M. et al. (2009) Contribution of vascular risk factors to the progression Alzheimer disease. Arch Neurol 66: 343–348.
39. Heyn P. Abreu B. Ottenbacher K. (2004) The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Physical Med Rehab 85: 1694–1704.
40. Imahori K. Uchida T. (1997) Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem 121: 179–188.
41. Jellinger K. (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Trans 109: 813–836.
42. Jorm A.F. (2000) Is depression a risk factor for dementia or cognitive decline? A review. Gerontology 46: 219–227.
43. Jorm A.F. (2001) History of depression as a risk factor for dementia: an updated review. Aust NZ J Psychiatry 35: 776–781.
44. Kalmijn S. Foley L. White C.M. Burchfiel J.D. Curb H. Petrovitch G.W. et al. (2000) Metabolic cardiovascular syndrome and risk of dementia in Japanese–American elderly men: the Honolulu–Asia Aging Study. Arterios Thromb Vasc Bio 20: 2255–2260.
45. Kivipelto M. Helkala E.L. Laakso M.P. Hänninen T. Hallikainen M. Alhainen K. (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322: b1447–b1451.
46. Kivipelto M. Ngandu T. Fratiglioni T. Viitanen M. Kåreholt I. Winblad B. (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62: 1556–1560.
47. Kivipelto M. Ngandu T. Laatikainen T. Winblad B. Soininen H. Tuomilehto J. (2006) Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population based study. Lancet Neurol 5: 735–741.
48. Lannfelt L. Blennow K. Zetterberg H. Batsman S. Ames D. Harrison J. et al. (2008) Safety, efficacy, and biomarker findings of PBT 2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7: 779–786.
49. Larrieu S. Letenneur L. Helmer C. Dartigues J.-F. Barberger-Gateau P. (2004) Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutrition Health Aging 8: 150–154.
50. Lautenschlager N.T. Cox K.L. Flicker L. Foster J.K. van Bockxmeer F.M. Xiao J. et al. (2008) Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300: 1027–1037.
51. Lee S. Chu K. Sim J. Heo J. Kim M. (2008) Panax Cinseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis Assoc Disord 22: 222–226.
52. Lobo A. Launer L. Fratiglioni L. Anderson K. Di Carlo A. Breteler M. et al. (2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurol 54: S4–S9.
53. Luchsinger J.A. Reitz C. Honig L.S. Tang M.X. Shea S. Mayeux R. (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65: 545–551.
54. Luengo-Fernandez, R., Leal, J. and Gray, A. (2010) Dementia 2010: The economic burden of dementia and associated research funding in the United Kingdom. A report produced by the Health Economics Research Centre, University of Oxford for the Alzheimer's Research Trust.
55. Mason S.E. McShane R. Ritchie C.W. (2010) Diagnostic tests for Alzheimer's disease: rationale, methodology, and challenges. Int J Alzheimer's Dis [ePub ahead of print].
56. Maynard C.J. Bush A.I. Masters C.L. Cappai R. Li Q.X. (2005) Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol 86: 147–159.
57. McGuinness B. Craig D. Bullock R. Passmore P. (2009 a) Statins for the prevention of dementia. Cochrane Database Syst Rev 2: CD003160–CD003160. DOI: 10.1002/14651858.CD003160.pub2.
58. McGuinness B. Todd S. Passmore P. Bullock R. (2009 b) Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 4: CD004034–CD004034. DOI: 10.1002/14651858.CD004034.pub3.
59. Mielke M. Rosenburg P. Tschanz J. Cook L. Corcoran C. Hayden K. et al. (2007) Vascular factors predict rate of progression in Alzheimer disease. Neurology 69: 1850–1858.
60. Moreira P.I. Zhu X. Wang X. Lee H.G. Nunomurac A. Petersen R.B. et al. (2010) Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 1802: 212–220.
61. Morris M. Evans D. Tangney C. Bienias J. Wilson R. Aggarwal N. et al. (2005) Relation of tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 81: 508–514.
62. Ohrui T. Tomita N. Sato-Nakagawa T. Matsui T. Maruyama M. Niwa K. et al. (2004) Effects of brain-penetrating ACE inhibitor on Alzheimer disease progression. Neurology 63: 1324–1325.
63. Ownby R.L. Crocco E. Acevedo A. John V. Loewenstein D. (2006) Depression a risk factor for alzheimer disease: systematic review, meta-analysis, and metaregession analysis. Arch Gen Psychiatry 63: 530–538.
64. Peters R. Poulter R. Warner J. Beckett N. Burch L. Bulpitt C. (2008) Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatrics 8: 36–37.
65. Peterson R. Thomas R. Grundman M. Bennett D. Doody R. Ferris S. et al. (2005) for the Alzheimer's disease cooperative study group. N Engl J Med 352: 2379–2388.
66. Pfizer and Medivation (2010) Pfizer and Medivation announce results from two phase 3 studies in dimebon (latrepirdine) Alzheimer's disease clinical development program, http://investors.medivation.com/releasedetail.Cfm?ReleaseID=448818.
67. Qiu C. von Strauss E. Fastbom J. Winblad B. Fratiglioni L. (2003) Low blood pressure and risk of dementia in the Kungsholmen Project: a 6-year follow-up study. Arch Neurol 60: 223–228.
68. Qiu C. Winblad B. (2005) The age dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4: 487–499.
69. Reiman E.M. Chen K. Langbaum J.B.S. Lee W. Reschke C. Brandy D. et al. (2010) Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage 49: 169–176.
70. Richard E. Kuiper R. Dijkgraaf M.G. van Gool W.A. (2009) Vascular care in patients with Alzheimer's disease with cerebrovascular lesions:a randomized clinical trial. J Am Geriat Soc 57: 797–805.
71. Ritchie K. Carrière I. Ritchie C.W. Berr C. Artero S. Ancelin M. (2010) Can we design prevention programs to reduce dementia incidence? A prospective study of modifiable risk factors. BMJ 5: 341–342.
72. Rosengren A. Skoog I. Gustafson D. Wilhelmsen L. (2005) Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 165: 321–326.
73. Roses A.D. Lutz M.W. Amrine-Madsen H. Saunders A.M. Crenshaw D.J. Sundseth S. et al. (2009) A TOMM 40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 10: 375–384.
74. Rovio S. Kareholt I. Helkala E.L. Viitanen M. Winblad B. Tuomilehto J. et al. (2005) Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 4: 705–711.
75. Rozzini L. Chilovi B. Bertoletti E. Conti M. Rio I. Trabucchi M. et al. (2006) Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatric Psychiatry 21: 550–555.
76. Saczynski J.S. Beiser A. Seshadri S. Auerbach S. Wolf P.A. Au R. (2010) Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology 5: 35–41.
77. Salloway S. Sperling R. Gilman S. Fox N.C. et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061–2070.
78. Scarmeas N. Luchsinger J.A. Schupf N. Brickman A.M. Cosentino S. Tang M.X. et al. (2009) Physical activity, diet, and risk of Alzheimer's disease. JAMA 302: 627–637.
79. Schnaider Beeri M. Goldbourt U. Silverman J.M. (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63: 1902–1907.
80. Shah K. Salah Q. Johnson M. Parikh N. Schulz P. Kunik M. (2009) Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatric Pharmacotherapy 7: 250–261.
81. Shepherd J. Blauw G.J. Murphy M.B. Bollen E.L.E.M. Buckley B.M. Cobbe S.M. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623–1630.
82. Singh-Manoux A. Marmot M. (2005) High blood pressure was associated with cognitive function in middle-age in the Whitehall II study. J Clin Epidemiol 58: 1308–1315.
83. Sitzer D. Twamley E. Jeste D. (2006) Cognitive training in Alzheimer's disease: a meta-analysis of the literature. Acta Psychiatrica Scandinavia 114: 75–90.
84. Sofi F. Cesari F. Abbate R. Gensini G.F. Casini A. (2008) Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337: b1344–b1344.
85. Sparks D. Scheff S. Liu H. Landers T. Coyne C. Hunsacker J. (1995) Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 131: 162–169.
86. Sparkes D. Sabbagh M. Connor D. Soares H. Lopez J. Stankovic G. et al. (2006) Statin therapy in Alzheimer's disease. Acta Neurologica Scandinavia 114 (Suppl 185): 78–86.
87. Sun Y. Lu C. Chien K. Chen S. Chen R. (2007) Efficacy of multivitamin supplementation containing vitamins B 6 and B 12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: A 26-week, randomised, double-blind, placebo-controlled study in Taiwanese patients. Clin Therapeut 29: 2204–2214.
88. Szwast S.J. Hendrie H.C. Lane K.A. Gao S. Taylor E. Unverzagt F. et al. (2007) Association of statin use with cognitive decline in elderly African Americans. Neurology 69: 1873–1880.
89. Whitmer R.A. Gunderson E.P. Barrett-Connor E. Quesenberry E.P. Jr Yaffe K. (2005 a) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330: 1360–1361.
90. Whitmer R.A. Sidney S. Selby J. Claiborne Johnston S. Yaffe K. (2005 b) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64: 277–281.
91. Whitmer R.A. Gustafson D.R. Barrett-Connor E. Haan M.N. Gunderson E.P. Yaffe K. (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71: 1057–1064.
92. Wilson R.S. Hoganson G.M. Rajan K.B. Barnes L.L. Mendes de Leon C.F. Evans D.A. (2010) Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology 75: 21–26.
93. Xu W. Caracciolo B. Wang H.X. Winblad B. Bäckman L. Qiu C. et al. (2010) Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes [ePub ahead of print].
94. Xu W. Qiu C. Gatz M. Pedersen N.L. Johansson B. Fratiglioni L. (2009) Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58: 71–77.
95. Xu W. Qiu C. Winblad B. Fratiglioni L. (2007) The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56: 211–216.
96. Yamada M. Kasagi F. Sasaki H. Masunari N. Mimori Y. Suzuki G. (2003) Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 51: 410–414.
97. Zandi P.P. Sparks L. Khachaturian A.S. Tschanz J. Norton M. Steinberg M. et al. (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62: 217–224.
98. Zou K. Gong J.S. Yanagisawa K. Michikawa M. (2002) A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 22: 4833–4841.